France's Sanofi to make vaccines from rival Pfizer-BioNTech
French drug maker Sanofi says it will help manufacture 125 million doses of the coronavirus vaccine developed by rivals Pfizer and BioNTech, while its own vaccine candidate faces delays
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.French drug maker Sanofi said Wednesday it will help manufacture 125 million doses of the coronavirus vaccine developed by rivals Pfizer and BioNTech, while its own vaccine candidate faces delays.
The Germany-based BioNTech will initially produce the vaccines at Sanofi facilities in Frankfurt, starting in the summer, according to a Sanofi statement. The company did not reveal financial details of the agreement.
The French government has been pressing Sanofi to use its facilities to help make vaccines from its rivals, given high demand and problems with supplies of the few vaccines that are already available.
“We are very conscious that the earlier vaccine doses are available, the more lives can potentially be saved,” Sanofi CEO Paul Hudson said in the statement.
Sanofi and British partner GlaxoSmithKline will start a new phase-2 trial of their COVID-19 vaccine next month, Sanofi said. The two companies said last month that their vaccine won’t be ready until late 2021 because the shot’s effectiveness in older people needed to be improved.
The European Union has been widely criticized for its slow rollout of a mass vaccination program. The bloc has approved using vaccines from Pfizer and Moderna, and its regulatory agency on Friday was to consider approval for the vaccine made by AstraZeneca and Oxford University.
___
Follow all of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak